31P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3 T

European Journal of Radiology

Volumn 73, Issue 2, 2010, Pages 255-259

  Shivu, Ganesh Nallur ^a   Abozguia, Khalid ^a   Phan, Thanh Trung ^a   Ahmed, Ibrar ^a   Henning, Anke ^b   Frenneaux, Michael ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ETH ZURICH   (Switzerland)

Author keywords

3 T; 31P spectroscopy; Cardiac magnetic resonance spectroscopy; Hypertrophic cardiomyopathy; Reproducibility

Indexed keywords

CARDIAC MAGNETIC RESONANCE; CLINICAL STUDY; FIELD STRENGTHS; HIGH-ENERGY PHOSPHATE; HYPERTROPHIC CARDIOMYOPATHY; IN-VIVO; IN-VIVO SPECTROSCOPY; PHILLIPS; REPRODUCIBILITIES; SENSITIVITY AND SPECIFICITY; SINGLE VOXEL; STANDARD DEVIATION; TRIPHOSPHATE;

HIGH ENERGY PHYSICS; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE DETECTORS; SIGNAL TO NOISE RATIO;

HEART;

2,3 DIPHOSPHOGLYCERIC ACID; ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; PHOSPHODIESTERASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; ENERGY TRANSFER; FEMALE; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; IN VIVO STUDY; MALE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REPRODUCIBILITY;

CARDIOMYOPATHY, HYPERTROPHIC; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MYOCARDIUM; PHOSPHATES; PHOSPHORUS ISOTOPES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 76349093379     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.10.018     Document Type: Article

References (31)

1. 31P NMR spectroscopy. Science 229 (1985) 769-772
2. 31P NMR magnetization transfer study. J Biol Chem 260 (1985) 3512-3517
3. Weiss R.G., Gerstenblith G., and Bottomley P.A. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci USA 102 (2005) 808-813
4. Nakae I., Mitsunami K., Omura T., et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol 42 (2003) 1587-1593
5. De Sousa E., Veksler V., Minajeva A., et al. Subcellular creatine kinase alterations. Implications in heart failure. Circ Res 85 (1999) 68-76
6. Abozguia K., Clarke K., Lee L., and Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 3 (2006) 490-498
7. Smith C.S., Bottomley P.A., Schulman S.P., Gerstenblith G., and Weiss R.G. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114 (2006) 1151-1158
8. Ye Y., Gong G., Ochiai K., Liu J., and Zhang J. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103 (2001) 1570-1576
9. 31P magnetic resonance spectroscopy. Lancet 338 (1991) 973-976
10. Neubauer S., Horn M., Cramer M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96 (1997) 2190-2196
11. Fragasso G., Perseghin G., De Cobelli F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27 (2006) 942-948
12. Weiss R.G., Bottomley P.A., Hardy C.J., and Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 323 (1990) 1593-1600
13. Maslov MY, Chacko VP, Stuber M, et al. Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. Am J Physiol Heart Circ Physiol 2007; 292:H387-91.
14. 31P-magnetic resonance spectroscopy. J Invest Med 45 (1997) 453-462
15. Conway M.A., Bottomley P.A., Ouwerkerk R., Radda G.K., and Rajagopalan B. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation 97 (1998) 1716-1723
16. Scheuermann-Freestone M., Madsen P.L., Manners D., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 107 (2003) 3040-3046
17. de Roos A., Doornbos J., Luyten P.R., Oosterwaal L.J., van der Wall E.E., and den Hollander J.A. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging 2 (1992) 711-719
18. 31P MR spectroscopy in hypertrophic cardiomyopathy: comparison with Tl-201 myocardial perfusion imaging. Am Heart J 125 (1993) 1323-1328
19. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97 (1998) 2536-2542
20. Crilley J.G., Boehm E.A., Blair E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41 (2003) 1776-1782
21. 31P magnetic resonance spectroscopy of mouse heart at 4.7 T. J Magn Reson Imaging 24 (2006) 1269-1276
22. Tyler D.J., Hudsmith L.E., Clarke K., Neubauer S., and Robson M.D. A comparison of cardiac (31)P MRS at 1.5 and 3 T. NMR Biomed 21 (2008) 793-798
23. Ordidge R.J., and Van de Vyver F.L. Re: separate water and fat MR images. Radiology 157 (1985) 551-553
24. Vanhamme L., Sundin T., Hecke P.V., and Huffel S.V. MR spectroscopy quantitation: a review of time-domain methods. NMR Biomed 14 (2001) 233-246
25. Cavassila S., Deval S., Huegen C., van Ormondt D., and Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed 14 (2001) 278-283
26. Metzler B., Schocke M.F., Steinboeck P., et al. Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson 4 (2002) 493-502
27. 31P spectroscopy. Magn Reson Med 48 (2002) 380-384
28. Schar M., Kozerke S., and Boesiger P. Navigator gating and volume tracking for double-triggered cardiac proton spectroscopy at 3 Tesla. Magn Reson Med 51 (2004) 1091-1095
29. Barker P.B., Hearshen D.O., and Boska M.D. Single-voxel proton MRS of the human brain at 1.5 and 3.0 T. Magn Reson Med 45 (2001) 765-769
30. Gruetter R., Weisdorf S.A., Rajanayagan V., et al. Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J Magn Reson 135 (1998) 260-264
31. Schar M., Kozerke S., Fischer S.E., and Boesiger P. Cardiac SSFP imaging at 3 Tesla. Magn Reson Med 51 (2004) 799-806